PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
Volume 5.25M
Average 1.04M
PDSB Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
PDS Biotechnology CorporationNASDAQ: PDSB
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $3.06B rose 93465.8% year over year, ahead of the +22461.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 134928.9% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -8.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.06B+134928.9% QoQ
- Last fiscal yearDec 2025
- $12.52M-8.6% YoY
- LTMMar 2026
- $3.07B+22461.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +93465.8% | -100.0% | -93565.8 pp |
| 1 year | -8.6% | -100.0% | -91.4 pp |
| 3-year CAGR | +0.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 12.52M USD
- Year-over-year change
- -8.6%
- 4-year CAGR
- +5.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.52M | -8.6% |
| FY2024 | 2024-12-31 | 13.7M | -10.4% |
| FY2023 | 2023-12-31 | 15.28M | +24.8% |
| FY2022 | 2022-12-31 | 12.24M | +20.2% |
| FY2021 | 2021-12-31 | 10.18M | — |
Selling, General & Admin vs competitors
How PDSB compares with its peers on the latest reported figures
- PDSB's LTM Mar 2026 selling, general & admin of $3.07B is the highest of the 6 companies compared; the peer median is $14.61M.
- Its year-over-year change of +22461.6% is the highest of 6, against a peer median of +9.3%.
- Over three fiscal years its annual growth of +0.7% compares with a peer median of +3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.07B | +22461.6% | +0.7% | — | |
| LTM Mar 2026 | $1.3B | +19278.2% | -20.7% | — | |
| LTM Mar 2026 | $27.78M | +2.3% | -0.3% | 51.9% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $14.61M | +87.7% | +55.5% | — |
| LTM Mar 2026 | $10.25M | +9.3% | +3.5% | — | |
| LTM Jun 2026 | $7.41M | -56.6% | +8.2% | 21.1% | |
| Peer median (excluding PDSB) | $14.61M | +9.3% | +3.5% | 36.5% | |
Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 57.33K | 59.79K | 0 |
| Gross Profit | 0 | 0 | (57.33K) | (59.79K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 11.25M | 29.43M | 27.76M | 22.57M | 19.03M |
| Selling, General & Admin | 10.18M | 12.24M | 15.28M | 13.7M | 12.52M |
| Operating Expenses | 21.44M | 41.67M | 43.05M | 36.26M | 31.54M |
| Depreciation & Amortization | 5.36K | 86 | 57.33K | 59.79K | 21.84K |
| EBITDA | (21.43M) | (40.74M) | (40.09M) | (33.75M) | (30.3M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.44M) | (41.67M) | (43.05M) | (36.32M) | (31.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4.35K | 935.18K | 2.9M | 2.52M | 1.22M |
| Interest Expense | 0 | 1.32M | 4.21M | 4.67M | 5.34M |
| Other Income / Expenses | 4.35K | (381.34K) | (1.3M) | (2.16M) | (4.12M) |
| Income Before Tax | (21.43M) | (42.05M) | (44.35M) | (38.48M) | (35.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.52M) | (1.2M) | (1.41M) | (869.17K) | (1.17M) |
| Net Income | (16.92M) | (40.85M) | (42.94M) | (37.61M) | (34.5M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| EPS (Diluted) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| Weighted Avg Shares | 25.6M | 28.6M | 30.95M | 36.45M | 46.38M |
| Weighted Avg Shares (Diluted) | 25.6M | 28.6M | 30.95M | 36.45M | 46.38M |
PDS Biotechnology Corporation
NASDAQ:PDSB
Intrinsic Alpha fair value
Locked
Current Price
$0.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.